IRIS UniCatt

Voso, Maria Teresa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.270
EU - Europa 4.963
AS - Asia 3.328
SA - Sud America 635
AF - Africa 81
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 7
Totale 14.299
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.181
DE - Germania 1.874
SG - Singapore 1.378
CN - Cina 1.304
SE - Svezia 733
PL - Polonia 583
BR - Brasile 543
UA - Ucraina 449
IT - Italia 353
FR - Francia 239
GB - Regno Unito 194
IE - Irlanda 182
IN - India 135
FI - Finlandia 116
ID - Indonesia 109
VN - Vietnam 102
RU - Federazione Russa 87
TR - Turchia 67
JP - Giappone 39
CA - Canada 36
NL - Olanda 33
BD - Bangladesh 30
MX - Messico 29
IQ - Iraq 28
AR - Argentina 26
HK - Hong Kong 23
BE - Belgio 19
CI - Costa d'Avorio 19
PK - Pakistan 18
ZA - Sudafrica 17
CO - Colombia 16
ES - Italia 16
AT - Austria 13
AU - Australia 13
KR - Corea 13
EC - Ecuador 10
GR - Grecia 10
IR - Iran 10
UZ - Uzbekistan 10
VE - Venezuela 10
CL - Cile 9
CZ - Repubblica Ceca 9
MA - Marocco 9
AE - Emirati Arabi Uniti 8
IL - Israele 8
LT - Lituania 8
PY - Paraguay 8
BG - Bulgaria 7
CH - Svizzera 7
KE - Kenya 7
PE - Perù 7
TH - Thailandia 7
TN - Tunisia 7
EG - Egitto 6
JO - Giordania 6
KZ - Kazakistan 6
ET - Etiopia 5
JM - Giamaica 5
BO - Bolivia 4
DO - Repubblica Dominicana 4
HN - Honduras 4
NO - Norvegia 4
RO - Romania 4
SA - Arabia Saudita 4
SK - Slovacchia (Repubblica Slovacca) 4
BH - Bahrain 3
CR - Costa Rica 3
HR - Croazia 3
PT - Portogallo 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BB - Barbados 2
BW - Botswana 2
DK - Danimarca 2
DZ - Algeria 2
EU - Europa 2
GE - Georgia 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LV - Lettonia 2
NI - Nicaragua 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PS - Palestinian Territory 2
UY - Uruguay 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BY - Bielorussia 1
GH - Ghana 1
GN - Guinea 1
IS - Islanda 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
Totale 14.290
Salva come PNG Salva come JPEG
Città #
Chandler 735
Singapore 638
Warsaw 569
Ashburn 447
Jacksonville 327
Beijing 222
Nanjing 216
San Mateo 207
Dearborn 188
Houston 177
Ann Arbor 174
Dublin 172
Wilmington 166
Woodbridge 161
Hangzhou 158
Los Angeles 158
Fairfield 120
New York 116
Nürnberg 112
Jakarta 101
Munich 101
Seattle 97
Chicago 95
Milan 84
Hefei 80
Nanchang 80
Lawrence 72
Bremen 71
Buffalo 63
Boston 62
Dallas 60
Cattolica 59
Redwood City 54
Moscow 53
São Paulo 53
Kunming 50
Izmir 44
Cambridge 42
Frankfurt am Main 42
Shanghai 35
Lancaster 33
Hanoi 32
Rome 32
Shenyang 32
Ho Chi Minh City 31
Marseille 31
University Park 30
Tianjin 29
Auburn Hills 28
Leawood 28
London 28
Salt Lake City 28
Changsha 25
Princeton 25
Hebei 23
Hong Kong 23
Jiaxing 23
Fremont 22
Falls Church 21
Kent 21
Zhengzhou 21
Norwalk 20
Abidjan 19
Santa Clara 19
Tokyo 19
Mountain View 18
Brussels 17
Chatsworth 16
Guangzhou 16
Helsinki 16
Detroit 15
The Dalles 15
Belo Horizonte 14
Pune 14
Rio de Janeiro 14
Augusta 13
Boardman 13
Jinan 13
Lanzhou 13
Philadelphia 13
Tampa 13
Atlanta 12
Brooklyn 12
Denver 11
Elk Grove Village 11
Curitiba 10
Montreal 10
Nuremberg 10
San Francisco 10
San Jose 10
Simi Valley 10
Toronto 10
Turku 10
Washington 10
Amsterdam 9
Baghdad 9
Brasília 9
Guarulhos 9
Portsmouth 9
San Diego 9
Totale 7.527
Salva come PNG Salva come JPEG
Nome #
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 404
Incidence of acute myeloid leukemia after breast cancer 363
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 338
Fanconi anemia gene variants in therapy-related myeloid neoplasms 302
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia 288
Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker 260
Therapy-related leukemias and myelodysplasia : susceptibility and incidence. 254
Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies 242
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. 215
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 215
MUTATIONAL ANALYSIS OF BONE MARROW MESENCHIMAL STROMAL CELLS IN MYELOID MALIGNANCIES 209
GSK3β down-regulation in Mesenchymal Stem Cells from patients with Myelodysplastic Syndrome. 208
Anemia in Diffuse Large B cell Non-Hodgkin Lymphoma: The Role of IL-6, Hepcidin and Erythropoietin 200
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma 198
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 197
DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA 191
Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia 190
Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. 187
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 182
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 173
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. 172
Why methylation is not a marker predictive of response to hypomethylating agents 171
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 169
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 169
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 167
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 167
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 166
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 163
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 162
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 161
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 160
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 159
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 158
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 158
Epigenetic changes in therapy-related MDS/AML 155
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine 154
Similarities and differences between therapy-related and elderly acute myeloid leukemia 151
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 146
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 145
Primary plasma cell leukemia followed by testicular plasmacytoma 144
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 144
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 141
Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia 141
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 140
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma 140
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 140
Iron in Hodgkin's lymphoma 139
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. 135
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. 134
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma 134
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. 134
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 132
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. 131
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 131
PU.1 and CEBPA expression in acute myeloid leukemia. 129
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 126
Small lymphocytic lymphoma in a patient with Fabry disease 124
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. 124
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. 121
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. 120
Outcome of therapy-related myeloid neoplasms treated with azacitidine 118
Clonal evolution in therapy-related neoplasms 116
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 112
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 111
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 111
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 109
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 109
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 109
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 108
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 107
Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial) 106
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 103
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 103
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression. 102
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 102
Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies 100
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 100
Negative prognostic value of glutathione s-transferase (gstm1 and gstt1) deletions in adult acute myeloid leukemia. 99
Therapy-related myeloid neoplasms: Clinical perspectives 98
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma) 96
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 96
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 95
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 91
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 89
Therapy-related myeloid neoplasms 86
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis 85
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 85
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 83
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 77
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 75
Efficacy and toxicicty of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer 74
Chronic myelomonocytic leukemia treatment with azacitidine: What have we learned so far? 72
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ) 72
Telomerase activity in human hematopoietic progenitor cells 71
Telomerase activity in human hematopoietic progenitor cells 67
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 63
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 63
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes 56
Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis 53
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile 53
Totale 14.298
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.853
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.853
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021843 0 0 0 0 0 131 201 26 129 78 247 31
2021/2022933 113 100 5 30 75 38 24 165 45 83 123 132
2022/20231.989 250 281 154 361 120 249 70 181 234 7 59 23
2023/2024835 40 259 15 20 33 148 34 34 13 24 109 106
2024/20251.956 45 61 151 60 184 32 99 73 280 135 567 269
2025/20262.364 679 123 234 386 786 156 0 0 0 0 0 0
Totale 14.373